FI963281A - Ureaasipohjainen rokote ja helicobakteeri-infektion hoito - Google Patents

Ureaasipohjainen rokote ja helicobakteeri-infektion hoito Download PDF

Info

Publication number
FI963281A
FI963281A FI963281A FI963281A FI963281A FI 963281 A FI963281 A FI 963281A FI 963281 A FI963281 A FI 963281A FI 963281 A FI963281 A FI 963281A FI 963281 A FI963281 A FI 963281A
Authority
FI
Finland
Prior art keywords
helicobacterial
urea
infection
treatment
based vaccine
Prior art date
Application number
FI963281A
Other languages
English (en)
Swedish (sv)
Other versions
FI963281A0 (fi
Inventor
Pierre Michetti
Irene Corthesy-Theulaz
Andre Blum
Catherine Davin
Rainer Haas
Jean-Pierre Kraehen-Buhl
Emilia Saraga
Original Assignee
Oravax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oravax Inc filed Critical Oravax Inc
Publication of FI963281A0 publication Critical patent/FI963281A0/fi
Publication of FI963281A publication Critical patent/FI963281A/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FI963281A 1994-02-23 1996-08-22 Ureaasipohjainen rokote ja helicobakteeri-infektion hoito FI963281A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/200,346 US6290962B1 (en) 1992-11-03 1994-02-23 Urease-based vaccine and treatment for helicobacter infection
PCT/US1995/002202 WO1995022987A1 (en) 1994-02-23 1995-02-23 Urease-based vaccine and treatment for helicobacter infection

Publications (2)

Publication Number Publication Date
FI963281A0 FI963281A0 (fi) 1996-08-22
FI963281A true FI963281A (fi) 1996-10-22

Family

ID=22741337

Family Applications (1)

Application Number Title Priority Date Filing Date
FI963281A FI963281A (fi) 1994-02-23 1996-08-22 Ureaasipohjainen rokote ja helicobakteeri-infektion hoito

Country Status (15)

Country Link
US (2) US6290962B1 (fi)
EP (1) EP0751786A4 (fi)
JP (1) JPH09509661A (fi)
AU (1) AU694195C (fi)
BR (1) BR9506884A (fi)
CA (1) CA2184057A1 (fi)
CZ (1) CZ250396A3 (fi)
FI (1) FI963281A (fi)
HU (1) HUT75374A (fi)
NO (1) NO963508L (fi)
NZ (1) NZ282535A (fi)
OA (1) OA10372A (fi)
PL (1) PL179149B1 (fi)
SK (1) SK109496A3 (fi)
WO (1) WO1995022987A1 (fi)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3919812B2 (ja) * 1993-07-27 2007-05-30 シーエスエル、リミテッド Ｈ．ピロリ関連胃十二指腸疾患の治療
US6406703B1 (en) 1993-07-27 2002-06-18 Csl Limited Treatment of H. pylori associated gastroduodenal disease
HUP9801266A3 (en) * 1995-04-28 1999-07-28 Oravax Inc Cambridge Multimeric, recombinant urease vaccine
CN1201395A (zh) * 1995-10-09 1998-12-09 科泰克斯国际有限公司 治疗幽门螺杆菌感染的方法
GB2307987A (en) * 1995-12-06 1997-06-11 Univ Manchester Epitopes of the urease of Helicobacter pylori as dignostic agents; pharmaceuticals comprising such epitopes or the antibodies thereto
SE9600647D0 (sv) * 1996-02-21 1996-02-21 Bror Morein Ny användning
ATE203678T1 (de) * 1996-04-15 2001-08-15 Anton Prof Dr Med Vet Dr Mayr Verwendung von multipotenten paramunitätsinducern aus attenuierten, nicht-immunogenen pockenviren oder parapockenviren zur herstellung von arzneimitteln
CA2252467A1 (en) * 1996-04-23 1997-10-30 Toray Industries, Inc. Antipylori agent
US6709656B1 (en) * 1996-06-10 2004-03-23 Thomas Boren Helicobacter pylori adhesin binding group antigen
US6248551B1 (en) * 1997-03-28 2001-06-19 Institut Pasteur Helicobacter aliphatic amidase AmiE polypeptides, and DNA sequences encoding those polypeptides
US20020026035A1 (en) * 1997-04-01 2002-02-28 Harold Kleanthous Helicobacter ghpo 1360 and ghpo 750 polypeptides and corresponding polynucleotide molecules
JP3430853B2 (ja) * 1997-04-11 2003-07-28 株式会社ゲン・コーポレーション 胃炎、胃潰瘍および十二指腸潰瘍の予防剤並びに治療剤
FR2762788B1 (fr) * 1997-04-30 2000-10-06 Pasteur Merieux Serums Vacc Composition vaccinale anti-helicobacter pour usage par voie systemique sous-diaphragmatique
WO1998048836A1 (fr) * 1997-04-30 1998-11-05 Merieux Oravax Composition vaccinale anti-helicobacter comprenant un adjuvant de type th1
FR2762787B1 (fr) * 1997-04-30 2000-10-06 Pasteur Merieux Serums Vacc Composition vaccinale anti-helicobacter comprenant un adjuvant de type th1
US20030158396A1 (en) * 1997-07-29 2003-08-21 Harold Kleanthous Identification of polynucleotides encoding novel helicobacter polypeptides in the helicobacter genome
US6599509B2 (en) 1997-09-02 2003-07-29 Massachusetts Institute Of Technology Compositions and methods comprising helicobacter antigens for treatment and prevention of inflammatory bowel disease
US5985631A (en) 1997-09-12 1999-11-16 Oravax-Merieux Co. Method for preventing the activation of inactive, recombinant Helicobacter pylori apourease
US20020151462A1 (en) * 1998-02-19 2002-10-17 Ling Lissolo Helicobacter pylori membrane proteins
GB9807721D0 (en) * 1998-04-08 1998-06-10 Chiron Spa Antigen
US6585975B1 (en) * 1998-04-30 2003-07-01 Acambis, Inc. Use of Salmonella vectors for vaccination against helicobacter infection
AU770498B2 (en) 1998-06-19 2004-02-26 Merieux Oravax LT and CT in parenteral immunization methods against helicobacter infection
US7384640B1 (en) * 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
US7041296B1 (en) * 1999-11-12 2006-05-09 The United States Of America As Represented By The Department Of Health And Human Services Methods of treating inflammatory bowel disease using cholera toxin B subunit
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
CA2351110A1 (en) * 2000-07-17 2002-01-17 Akzo Nobel N.V. Helicobacter felis vaccine
EP1404368B1 (en) 2001-06-07 2009-12-09 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
CN1541111A (zh) * 2001-06-07 2004-10-27 ���Ͽع����޹�˾ 作为佐剂的霍乱全毒素的突变形式
EP1458362A4 (en) * 2001-11-19 2006-01-18 Becton Dickinson Co PHARMACEUTICAL COMPOSITIONS IN PARTICLE FORM
US7357949B2 (en) * 2001-12-21 2008-04-15 Agion Technologies Inc. Encapsulated inorganic antimicrobial additive for controlled release
US20030118658A1 (en) * 2001-12-21 2003-06-26 Trogolo Jeffrey A. High aspect ratio encapsulated inorganic antimicrobial additive for controlled release
FR2837835B1 (fr) * 2002-03-29 2007-06-22 Maria Urdaci Souche bacillus subtilis cu1, son utilisation comme agent immunomodulateur du systeme immunitaire et vaccin recombinant vivant contre h. pylori la contenant
CN1212126C (zh) * 2002-07-09 2005-07-27 中国科学院长春应用化学研究所 纳米羟基磷灰石补钙剂
JP2004041084A (ja) * 2002-07-11 2004-02-12 Japan Science & Technology Corp ヘリコバクター・ピロリ菌に対するワクチン用ペプチド、それをコードする遺伝子、その遺伝子が導入された形質転換体、及びそれらの利用方法
ES2443416T3 (es) 2002-07-18 2014-02-19 Helix Biopharma Corp. Uso de ureasa para inhibir el crecimiento de células cancerosas
US7264800B2 (en) 2002-07-18 2007-09-04 Helix Biopharma Corporation Method and composition for inhibiting cancer cell growth
US20040109905A1 (en) * 2002-09-18 2004-06-10 Debasis Bagchi Method and composition of anthocyanin-rich berry extracts that prevents or inhibits angiogenesis and helicobacter pylori and acts as a powerful antioxidant that provides various health benefits
EP1773990A2 (en) * 2004-08-04 2007-04-18 Applied Research Systems ARS Holding N.V. Capsules containing transfected cells, method for preparing the same and use thereof for immunization and vaccination
JP2008509168A (ja) 2004-08-13 2008-03-27 マーシャル，バリー，ジェー． 細菌デリバリシステム
US8029777B2 (en) * 2004-08-13 2011-10-04 Marshall Barry J Helicobacter system and uses thereof
AU2007317206B2 (en) * 2006-11-10 2013-04-18 Ondek Pty Ltd Methods and devices for the delivery of peptides into the gastric mucosa
PL218700B1 (pl) 2012-03-29 2015-01-30 Gdański Univ Medyczny Doustna szczepionka zawierająca przetrwalniki Bacillus subtilis oraz jej zastosowanie do immunizacji przeciwko Helicobacter pylori
CN103461685B (zh) * 2012-06-07 2014-10-22 中国农业科学院北京畜牧兽医研究所 瘤胃脲酶抗原组合物及其制备方法和应用及瘤胃脲酶抗原蛋白的应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268278A (en) * 1984-03-30 1993-12-07 Istituto Farmacologico Serono S.P.A. Genetic expression of somatostatin as hybrid polypeptide
US4879213A (en) * 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
US5268276A (en) * 1988-09-16 1993-12-07 Jan Holmgren Recombinant systems for expression of cholera B-sub-unit with the aid of foreign promoters and/or leader peptides
FR2637612B1 (fr) * 1988-10-06 1993-09-10 Pasteur Institut Sequences de nucleotides codant pour une proteine a activite ureasique
US5443832A (en) 1990-04-16 1995-08-22 Institut Swisse De Recherches Experimentales Sur Le Cancer Hydroxyapatite-antigen conjugates and methods for generating a poly-Ig immune response
DE69333585T2 (de) 1992-02-26 2005-07-28 Vanderbilt University, Nashville Gereinigtes vakuolisierendes toxin aus helicobacter pylori und methoden zu dessen verwendung
US5859219A (en) 1992-02-26 1999-01-12 Vanderbilt University Purified vacuolating toxin from Helicobacter pylori and methods to use same
WO1993018150A1 (en) * 1992-03-02 1993-09-16 Biocine S.P.A. Helicobacter pylori proteins useful for vaccines and diagnostics
MX9301706A (es) * 1992-04-13 1994-05-31 Oravax Inc Composicion de vacuna para el tratamiento de la infeccion por helicobacter.
ATE161181T1 (de) * 1992-07-06 1998-01-15 Nestle Sa Lactobacillus acidophilus enthaltende antigastritis-mittel
US5403924A (en) 1992-10-13 1995-04-04 Vanderbilt University Taga gene and methods for detecting predisposition to peptic ulceration
US5733740A (en) 1992-10-13 1998-03-31 Vanderbilt University Taga gene and methods for detecting predisposition to peptic ulceration and gastric carcinoma
US5972336A (en) * 1992-11-03 1999-10-26 Oravax Merieux Co. Urease-based vaccine against helicobacter infection
JP3919812B2 (ja) 1993-07-27 2007-05-30 シーエスエル、リミテッド Ｈ．ピロリ関連胃十二指腸疾患の治療
AUPM612494A0 (en) * 1994-06-08 1994-06-30 Csl Limited Treatment or prevention of helicobacter infection
DE19521314A1 (de) * 1995-06-12 1996-12-19 Max Planck Gesellschaft Adhärenzgen aus Helicobacter pylori und davon codiertes Polypeptid
DE19521312A1 (de) * 1995-06-12 1996-12-19 Max Planck Gesellschaft Verfahren zur Identifizierung sekretorischer Gene aus Helicobacter pylori
DE19535321A1 (de) * 1995-09-22 1997-03-27 Max Planck Gesellschaft Neues Adhäsin aus Helicobacter pylori
GB2307987A (en) * 1995-12-06 1997-06-11 Univ Manchester Epitopes of the urease of Helicobacter pylori as dignostic agents; pharmaceuticals comprising such epitopes or the antibodies thereto
FR2745186B1 (fr) * 1996-02-26 1998-12-31 Torossian Fernand Narbey Complexe immunomodulateur et ses utilisations pour le traitement et la prevention des recidives des affections par helicobacter
AU2304097A (en) * 1996-04-05 1997-10-29 Kieta Holding S.A. Compositions and methods relating to drug discovery and detection and treatment of gastrointestinal diseases
US20030069404A1 (en) * 1996-11-14 2003-04-10 Rainer Haas Helicobacter antigens and corresponding DNA fragments
US20030023066A1 (en) * 1996-11-14 2003-01-30 Rainer Haas Helicobacter polypeptides and corresponding polynucleotide molecules
US6248551B1 (en) * 1997-03-28 2001-06-19 Institut Pasteur Helicobacter aliphatic amidase AmiE polypeptides, and DNA sequences encoding those polypeptides
US5985631A (en) * 1997-09-12 1999-11-16 Oravax-Merieux Co. Method for preventing the activation of inactive, recombinant Helicobacter pylori apourease
EP1278768B1 (en) * 2000-04-27 2006-11-15 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for identifying helicobacter antigens

Also Published As

Publication number Publication date
PL316007A1 (en) 1996-12-23
EP0751786A1 (en) 1997-01-08
BR9506884A (pt) 1997-08-19
SK109496A3 (en) 1997-07-09
NO963508D0 (no) 1996-08-22
NZ282535A (en) 2001-03-30
US20030007980A1 (en) 2003-01-09
AU694195B2 (en) 1998-07-16
AU1968195A (en) 1995-09-11
PL179149B1 (pl) 2000-07-31
EP0751786A4 (en) 1999-12-29
OA10372A (en) 2001-11-14
FI963281A0 (fi) 1996-08-22
WO1995022987A1 (en) 1995-08-31
NO963508L (no) 1996-10-21
AU694195C (en) 2001-07-19
HU9602310D0 (en) 1996-10-28
US6290962B1 (en) 2001-09-18
CZ250396A3 (en) 1996-12-11
CA2184057A1 (en) 1995-08-31
JPH09509661A (ja) 1997-09-30
HUT75374A (en) 1997-05-28

Similar Documents

Publication Publication Date Title
FI963281A (fi) Ureaasipohjainen rokote ja helicobakteeri-infektion hoito
NO934547D0 (no) Oral behandling av Helicobacter-in-feksjon
IS5191A (is) Örverueyðandi hindrun og meðferð gegn eyðniveirunni og öðrum smitsjúkdómum í mönnum
DE69132274T2 (de) Methode der bakteriellen attenuierung und impfstoff
FI952926A0 (fi) Menetelmät allergioiden hoitamiseksi tai ehkäisemiMenetelmät allergioiden hoitamiseksi tai ehkäisemiseksi seksi
FI971969A (fi) Peräpukamien hoitoon tarkoitettuja koostumuksia ja käyttömenetelmä
NO914352L (no) Fremgangsmaate for behandling av brukte katodebunner
NO910340L (no) Topiske preparater for behandling av menneskenegler.
DE69426690T2 (de) Behandlung von atrophischer Haut und Vagina
EE9800234A (et) Ravimeetod ja farmatseutiline kompositsioon
EE9400183A (et) Inimese immuunpuudulikkuse viiruse vaktsiin ja kasutamine
FI965204A (fi) Bromelaiinin lääkekäyttö
DE69620691D1 (de) Therapeutisches Mittel zur Behandlung der Hypercholesterinämie
NO307930B1 (no) Benzo[f]kinolinoner, farmasøytisk formulering omfattende samme og anvendelse av samme for fremstilling av formulering for behandling
ID21874A (id) Penggunaan 1-hidroksi-2-piridon untuk pengobatan infeksi urap kulit
FI963638A (fi) Menetelmiä HIV-1-injektion diagnosoimiseksi ja hoitamiseksi
ID16598A (id) Metode pencegahan dan pengobatan penyakit-penyakit infeksi virus
FI953087A (fi) Selluloosa-aineen käsittely ja siinä käytettävät koostumukset
FI971897A0 (fi) Ihmisen retrovirusinfektion detektointi
NO965591D0 (no) Kombinasjonsbehandling av HIV-infeksjon
FI971403A (fi) Menetelmä voimistettujen antigeenisten enteeristen bakteerien ja niitä sisältävien rokotteiden tuottamiseksi
FI925349A (fi) Menetelmä hygieniaa vaativiin olosuhteisiin tarkoitetun suojavaatteen valmistamiseksi sekä vastaava kertakäyttöinen suojavaate
FI963263A (fi) Bromelaiinin lääkinnällinen käyttö
FI961869A0 (fi) Rokotteen suunnittelu ja valmistus
NO307285B1 (no) Anvendelse av eliprodil og enantiomerer derav for fremstilling av medisinske preparater